Sreeja Attur Selected Research

Type 1 Diabetes Mellitus (Autoimmune Diabetes)

1/2015	The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.
1/2013	Activation of ErbB2 and Downstream Signalling via Rho Kinases and ERK1/2 Contributes to Diabetes-Induced Vascular Dysfunction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sreeja Attur Research Topics

Disease

2	Hyperglycemia 01/2015 - 01/2015
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2015 - 01/2013
1	Heart Failure 07/2017

Drug/Important Bio-Agent (IBA)

1	angiotensin I (1-7)IBA 01/2015
1	D-Pro7-Ang-(1-7)IBA 01/2015
1	Lapatinib (GW572016)FDA Link 01/2015
1	Glucose (Dextrose)FDA LinkGeneric 01/2015
1	Streptozocin (Streptozotocin)FDA Link 01/2015
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2013
1	ErbB Receptors (EGF Receptor)IBA 01/2013

Therapy/Procedure

1	Blood Transfusion (Blood Transfusions) 07/2017
1	Length of Stay 07/2017